activity Weight Loss Associated wiht Use of Anti-Obesity Medications in older adults: A Systemic Review
activity How do we SELECT medications and SUSTAIN their impact? Clinical approaches obesity treatment
activity Nutrient-stimulated hormone-based pharmacotherapy for the treatment of obesity: Sparks from the pipeline!
activity Treating the Chronic Disease of Obesity
activity Amylin for the Treatment of Metabolic Disease: Clinical Insights
activity Care in Obesity and Metabolic Health”
activity Transforming Obesity Care: Bridging research and clinical practice.
activity Nutrient-stimulated hormone-based pharmacotherapy for the treatment of obesity: Sparks from the pipeline!
activity When Treating New Onset Type 2 Diabetes… Treat Obesity First!”
activity The Future of Anti-Obesity Pharmacotherapy: Sparks from the Pipeline.
activity Anti-Obesity Pharmacotherapy” and “Anti-Obesity Pharmacotherapy for Adolescent Obesity”, and “Obesity Pharmacotherapy
activity Symposium: SURMOUNT-OSA Trial Results and the Potential Role of Tirzepatide in Treating Obesity-Relates Obstructive Sleep Apnea.”
activity GIP/GLP-1/Glucagon Receptor Agonist for Obesity
activity Once-weekly Triple Receptor (GIP/GLP-1/Glucagon) Agonist Retatrutide (LY3437943): Efficacy and Safety in a 48-week Obesity Phase 2 Trial
activity Nutrient-stimulated Hormone-based pharmacotherapy for the treatment of obesity: Sparks from the pipeline!
activity "From Awareness to Action: How do We Treat Adolescent Obesity" and "Once -Weekly Triple Receptor (GIP/GLP-1/Glucagon) Agonist Retatrutide (LY3437943): Efficacy and Safety in a 48-Week Obesity Phase 2 Trial" and "Different Targets for Different Patients"
activity "Once-weekly Triple Receptor (GIP/GLP-1/Glucagon) Agonist Retatrutide (LY3437943): Efficacy and Safety in a 48-week Obesity Phase 2 Trial" and "Retatrutide T2D: Efficacy and Safety Results of the 36-week T2D Phase 2 Trial"
activity Anti-obesity medications for the treatment of obesity: the importance of optimizing health - muscle matters
activity Anti-obesity medications for the treatment of obesity: Sparks from the pipeline
activity Nutrition-stimulated hormone-based medication for obesity treatment: Sparks from the pipeline